The<unk>  conducted an advisory committee<unk>  regarding the approvability of<unk>  for reduction of stroke and systemic embolization in patients with non-valvular atrial fibrillation on September 8th, 2011.
Rivaroxaban FDA review of ROCKET AF data
Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial
ST elevation myocardial infarction glycoprotein IIbIIIa inhibition
Antiplatelet therapy to support PCI
Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for warfarin therapy
Chronic stable angina treatment clopidogrel
Unstable angina / non ST elevation myocardial infarction GPIIb/IIIa inhibitor
Unstable angina / non ST elevation myocardial infarction factor Xa inhibitors therapy